1. Home
  2. Press release
Sep 17, 2020 09:59 JST

Source: Eisai

Eisai Establishes Pharma Sales Subsidiary in Vietnam

TOKYO, Sep 17, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has established a new pharmaceutical sales subsidiary in Ho Chi Minh City, the Socialist Republic of Viet Nam (Vietnam), which will be named Eisai Vietnam Co., Ltd. (Eisai Vietnam). Eisai Vietnam is a wholly-owned subsidiary of Eisai.

The pharmaceutical market in Vietnam is surpassed in size only by those of Thailand and the Philippines within the Association of Southeast Asian Nations (ASEAN), with the market size reaching 4,199 million USD in 20191. The compound annual growth rate of the Vietnamese pharmaceutical market from 2014 to 2019 was +10.6%(1), and it is expected that this market rate will continue to grow in the double digits. In 1992, Eisai (Thailand) Marketing Co., Ltd., a pharmaceutical sales subsidiary of Eisai, started business in Vietnam through a local agency. Eisai opened a representative office in Ho Chi Minh City in 1995, and mainly markets the proton-pump inhibitor Pariet, muscle relaxant Myonal, peripheral neuropathy treatment Methycobal, and others.

In addition, regarding its global products in Vietnam, Eisai recently launched its antiepileptic drug Fycompa in October 2019, and obtained marketing approval for the anti-cancer agent Lenvima in June 2020. Eisai has also filed for regulatory approval for the in-house developed anti-cancer agent Halaven.

With the establishment of Eisai Vietnam, Eisai aims to enhance its own drug sales system in Vietnam, deliver innovative new drugs to more patients in Vietnam, and contribute to improving the benefits of patients and their families.

(1) Copyright 2020 IQVIA Created based on IQVIA Analytics Link 2014-2019. Unauthorized reproduction prohibited.

Contact:
Media Inquiries:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
October 14 2025 16:54 JST
 
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
October 08 2025 11:03 JST
 
Eisai Highlights Breadth of Oncology Research at ESMO 2025
October 03 2025 17:01 JST
 
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
September 29 2025 09:33 JST
 
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia
September 24 2025 18:04 JST
 
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
September 17 2025 17:20 JST
 
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
September 12 2025 12:20 JST
 
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
September 08 2025 16:49 JST
 
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
September 04 2025 09:56 JST
 
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
September 03 2025 10:32 JST
 
More Press release >>

Latest Press Release


MHI Thermal Systems Air-Conditioners for the Australian Market Recognized with Prestigious Awards
Oct 17, 2025 23:37 JST

SEKISUI CHEMICAL, Fujitsu, and SAP Japan announce comprehensive modernization of management platform to drive data-driven approach
Oct 17, 2025 23:00 JST

TransNusa to Launch Bali - Singapore Scheduled Flight on November 17
Oct 17, 2025 16:58 JST

MHIEC Receives Contract for Improvement of Core Equipment at Municipal Solid Waste Incineration Facility in Kanazawa
Oct 16, 2025 23:57 JST

Overview of Honda Exhibits at Japan Mobility Show 2025
Oct 16, 2025 23:20 JST

DENSO to Exhibit at JAPAN MOBILITY SHOW 2025
Oct 16, 2025 22:53 JST

Fujitsu and IISc launch joint research on advanced AI technologies to accelerate new material development and resolve societal challenges
Oct 16, 2025 21:55 JST

Mitsubishi Motors Wins Triple Honors at Good Design Award 2025 in Japan with the Delica Mini, Destinator and Delica Series
Oct 15, 2025 21:29 JST

Mitsubishi Motors at Japan Mobility Show 2025: World Premiere of Electrified Crossover SUV Concept
Oct 15, 2025 20:35 JST

Honda to Present World Premiere of ProZision(TM) Autonomous, at Equip Exposition 2025, Honda Battery-powered Autonomous Riding Lawn Mower
Oct 15, 2025 19:56 JST

Honda to Make Additional Investment in U.S.-based Helm.ai to Further Enhance Development of Next-generation AD/ADAS
Oct 15, 2025 19:25 JST

MHI Thermal Systems Wins 2025 GOOD DESIGN AWARD for Hyper Multi LXZ Series of Building-Use Multi-Split Air-Conditioners in Japan
Oct 15, 2025 18:50 JST

Mitsubishi Power Marks 60 Years in Saudi Arabia with Unveiling of First Locally Assembled JAC Gas Turbine at Dammam Assembly Facility
Oct 14, 2025 18:21 JST

LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
Oct 14, 2025 17:54 JST

Mazda Announces Exhibition at JAPAN MOBILITY SHOW 2025
Oct 14, 2025 17:38 JST

Hitachi Advances Strategic Alliance with Google Cloud to Empower Frontline Workers with Field-Specific AI Agents
Oct 11, 2025 00:58 JST

Honda Issues Integrated Report - "Honda Report 2025"
Oct 11, 2025 00:46 JST

DENSO's Electrification Products Adopted for TOYOTA's New "bZ4X"
Oct 11, 2025 00:21 JST

Newly developed eAxle adopted for TOYOTA's new "bZ4X"
Oct 11, 2025 00:08 JST

MHIET and MHI-TC Complete Delivery of First "COORDY" Controller Providing Optimized Control of Multiple Power Sources
Oct 10, 2025 23:47 JST
 More Latest Release >>